Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01614990 · ClinicalTrials.gov registry record · Phase 2
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
A Phase 2 study of Cancer Cachexia, sponsored by Garcia, Jose M., MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01614990 is a Phase 2 study of Cancer Cachexia that has completed, run by Garcia, Jose M., MD, PhD. The registered enrollment target is 15 participants, below the 139-participant average among 6 other Cancer Cachexia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01614990, a Phase 2 study of Cancer Cachexia, has completed, sponsored by Garcia, Jose M., MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Macimorelin
Study Locations (1)
Washington
- Veterans Affairs Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-05 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01614990
The ClinicalTrials.gov registry entry for NCT01614990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 6 other Cancer Cachexia trials with a reported enrollment target (89% lower). The listed sponsor is Garcia, Jose M., MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer Cachexia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01614990 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01614990 about?
NCT01614990 is a clinical study titled "Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia". The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
What is the current status of trial NCT01614990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-05. Estimated completion is 2021-12.
What conditions does trial NCT01614990 study?
This clinical trial studies the following conditions: Cancer Cachexia.
What interventions are being tested in trial NCT01614990?
The interventions under investigation include: Placebo (DRUG), Macimorelin (DRUG).
Who is sponsoring clinical trial NCT01614990?
This trial is sponsored by Garcia, Jose M., MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01614990 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Cachexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
RECRUITING · Phase 2
-
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
COMPLETED · Phase 2
-
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
COMPLETED · Phase 2
-
A First-in-Human Study of FID-022 in Solid Tumor Patients
RECRUITING
-
Florida Pancreas Collaborative Next Generation Biobank
ACTIVE NOT RECRUITING
-
Vitamin D for Muscle Metabolic Function in Cancer Cachexia
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.